BRCA2 and breast cancer: In the absence of available clinical data, we sought to answer these questions by combining functional analysis of HR status with molecular profiling of a collection of matched PARPi-naive and PARPi-resistant mouse mammary tumors that harbor large intragenic deletions of Brca1 or Brca2 genes that cannot be spontaneously restored.